When is Bysanti expected to launch in the U.S.?

Vanda Pharmaceuticals expects to launch Bysanti in the U.S. in the third quarter.

How does Bysanti work?

Bysanti is an atypical antipsychotic that works by blocking dopamine and serotonin receptors in the brain.

Home / Health / FDA Greenlights Vanda's Bysanti for Mental Health

FDA Greenlights Vanda's Bysanti for Mental Health

Q: What conditions does Vanda Pharmaceuticals' Bysanti treat?

Bysanti is approved for the treatment of schizophrenia and acute bipolar I disorder.

21 Feb

•

Summary

Vanda Pharmaceuticals' Bysanti drug is now FDA-approved.
The drug treats schizophrenia and acute bipolar I disorder.
Launch in the U.S. is expected in the third quarter.

FDA Greenlights Vanda's Bysanti for Mental Health

The U.S. Food and Drug Administration has granted approval for Vanda Pharmaceuticals' new drug, Bysanti, indicated for the treatment of schizophrenia and acute bipolar I disorder. This decision by the FDA is a notable development for Vanda Pharmaceuticals, expanding its portfolio of psychiatric medications.

Bysanti, chemically known as milsaperidone, operates within the class of atypical antipsychotics. These medications work by influencing dopamine and serotonin receptors in the brain, which are key in regulating mood and cognitive functions.